Sitravatinib (MGCD516) is an inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Met, c-Kit, PDGFRα/β, PDGFR, and Axl.
| Pack Size | Availability | Price/USD | Quantity |
|---|---|---|---|
| 5 mg | In stock | $ 103 | |
| 10 mg | In stock | $ 185 | |
| 20 mg | In stock | $ 312 | |
| 50 mg | In stock | $ 500 | |
| 100 mg | In stock | $ 775 |
| Description | Sitravatinib (MGCD516) is an inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Met, c-Kit, PDGFRα/β, PDGFR, and Axl. |
| Targets&IC50 | DDR2: 0.5 nM, EPHA3: 1 nM, Mer: 2 nM, VEGFR3 (FLT4): 2 nM, Axl: 1.5 nM |
| In vitro | Cell lines: DDLS,LS141,and MPNST. Concentrations: 62.5,125,250,500,1000,2000 nM2,000-3,000 cells were plated in 96-well plates in RPMI/DME media with 10% FBS and then treated with the indicated drugs the next day.After 72 hours,media was replaced with 100 μL of media with 10% serum and 10% CCK-8 solution.After 1 hour,the optical density was read at 450 nm to determine viability.Background values from negative control wells without cells were subtracted for final sample quantification.Data was plotted as % cell viability compared to DMSO control. |
| In vivo | Animal Models: ICR/SCID mice. Formulation: 0.5% hydroxypropyl methylcellulose (HPMC) and 0.1% Tween-80 solution (pH 1.4). Dosages: 15 mg/kg. Administration: p.o. |
| Synonyms | MG516, MGCD516 |
| CAS No. | 1123837-84-2 |
| Chemical Formula | C33H29F2N5O4S |
| Molecular Weight | 629.68 |
| Solubility | DMSO: 32 mg/mL |
| Storage | Powder: -20°C for 2 years In solvent: -80°C for 1 year |
In vivo Formulation Calculator (Clear solution)Calculatorbottom
